Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Wilmington, United States
Countries of investment
  • United States
Investment stages
  • Series A
  • Series B
Industries
  • Biotechnology
  • Health Tech
  • Life Sciences
  • Pharma
About
Ascenta Capital focuses on advancing biotech companies through Phase 1 and Phase 2 clinical development. The firm provides strategic capital and operational support to help high-potential therapeutics reach key inflection points and prepare for later-stage partnerships or exits.
Min check size
$2M
Max check size
$30M
Fund size
NPS

Investment Thesis

Ascenta Capital invests in development-stage biotechnology companies with strong clinical potential in the United States.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

The leadership team has over 15 years of experience in biotech venture capital and corporate finance, with a focus on clinical-stage investments and value creation through science-driven companies.

Ascenta Capital Contacts Information

Primary contact

Secondary contact

Team

EVAN RACHLIN

MD – Co-Founder and Managing Partner

LORENCE KIM

MD – Co-Founder and Managing Partner

JEFF CHODAKEWITZ

MD – Advisory Partner

Portfolio

Belharra Therapeutics

Tectonic Therapeutic

ROME Therapeutics

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp